Compare · COR vs COSM
COR vs COSM
Side-by-side comparison of Cencora Inc. (COR) and Cosmos Health Inc. (COSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and COSM operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $51.29B, about 3467.8x COSM ($14.8M).
- Over the past year, COR is down 9.5% and COSM is down 97.3% - COR leads by 87.8 points.
- COSM has been more active in the news (13 items in the past 4 weeks vs 5 for COR).
- COR has more recent analyst coverage (25 ratings vs 0 for COSM).
- Company
- Cencora Inc.
- Cosmos Health Inc.
- Price
- $263.65-0.42%
- $0.25-5.59%
- Market cap
- $51.29B
- $14.8M
- 1M return
- -13.16%
- -30.92%
- 1Y return
- -9.54%
- -97.32%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 13
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
Latest COR
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SD filed by Cencora Inc.
- Director Durcan Dermot Mark bought $1,065,040 worth of shares (4,000 units at $266.26), increasing direct ownership by 17% to 27,767 units (SEC Form 4)
- Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
- Cencora Announces Updated Fiscal Year 2026 Financial Outlook
- SEC Form 10-Q filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Reports Fiscal 2026 Second Quarter Results
- Director Tyler Lauren M was granted 99 shares, increasing direct ownership by 3% to 3,809 units (SEC Form 4)
- Director Cooper Ellen was granted 99 shares, increasing direct ownership by 14% to 796 units (SEC Form 4)
Latest COSM
- SEC Form DEF 14A filed by Cosmos Health Inc.
- Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline
- Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
- SEC Form PRE 14A filed by Cosmos Health Inc.
- Cosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
- Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
- SEC Form 10-Q filed by Cosmos Health Inc.
- SEC Form NT 10-Q filed by Cosmos Health Inc.
- Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program